{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T23:49:48Z","timestamp":1791330588007,"version":"4.3.1"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,1,15]],"date-time":"2024-01-15T00:00:00Z","timestamp":1705276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,1,15]],"date-time":"2024-01-15T00:00:00Z","timestamp":1705276800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100010269","name":"Wellcome Trust","doi-asserted-by":"publisher","award":["Other"],"award-info":[{"award-number":["Other"]}],"id":[{"id":"10.13039\/100010269","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010269","name":"Wellcome Trust","doi-asserted-by":"publisher","award":["Other"],"award-info":[{"award-number":["Other"]}],"id":[{"id":"10.13039\/100010269","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010269","name":"Wellcome Trust","doi-asserted-by":"publisher","award":["Other"],"award-info":[{"award-number":["Other"]}],"id":[{"id":"10.13039\/100010269","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010269","name":"Wellcome Trust","doi-asserted-by":"publisher","award":["223195\/Z\/21\/Z"],"award-info":[{"award-number":["223195\/Z\/21\/Z"]}],"id":[{"id":"10.13039\/100010269","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010269","name":"Wellcome Trust","doi-asserted-by":"publisher","award":["Other"],"award-info":[{"award-number":["Other"]}],"id":[{"id":"10.13039\/100010269","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010269","name":"Wellcome Trust","doi-asserted-by":"publisher","award":["Other"],"award-info":[{"award-number":["Other"]}],"id":[{"id":"10.13039\/100010269","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010269","name":"Wellcome Trust","doi-asserted-by":"publisher","award":["Other"],"award-info":[{"award-number":["Other"]}],"id":[{"id":"10.13039\/100010269","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010269","name":"Wellcome Trust","doi-asserted-by":"publisher","award":["223195\/Z\/21\/Z"],"award-info":[{"award-number":["223195\/Z\/21\/Z"]}],"id":[{"id":"10.13039\/100010269","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010269","name":"Wellcome Trust","doi-asserted-by":"publisher","award":["Other"],"award-info":[{"award-number":["Other"]}],"id":[{"id":"10.13039\/100010269","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010269","name":"Wellcome Trust","doi-asserted-by":"publisher","award":["Other"],"award-info":[{"award-number":["Other"]}],"id":[{"id":"10.13039\/100010269","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010269","name":"Wellcome Trust","doi-asserted-by":"publisher","award":["Other"],"award-info":[{"award-number":["Other"]}],"id":[{"id":"10.13039\/100010269","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010269","name":"Wellcome Trust","doi-asserted-by":"publisher","award":["Other"],"award-info":[{"award-number":["Other"]}],"id":[{"id":"10.13039\/100010269","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010269","name":"Wellcome Trust","doi-asserted-by":"publisher","award":["Other"],"award-info":[{"award-number":["Other"]}],"id":[{"id":"10.13039\/100010269","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010269","name":"Wellcome Trust","doi-asserted-by":"publisher","award":["Other"],"award-info":[{"award-number":["Other"]}],"id":[{"id":"10.13039\/100010269","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010269","name":"Wellcome Trust","doi-asserted-by":"publisher","award":["Other"],"award-info":[{"award-number":["Other"]}],"id":[{"id":"10.13039\/100010269","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010269","name":"Wellcome Trust","doi-asserted-by":"publisher","award":["Other"],"award-info":[{"award-number":["Other"]}],"id":[{"id":"10.13039\/100010269","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010269","name":"Wellcome Trust","doi-asserted-by":"publisher","award":["Other"],"award-info":[{"award-number":["Other"]}],"id":[{"id":"10.13039\/100010269","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010269","name":"Wellcome Trust","doi-asserted-by":"publisher","award":["Other"],"award-info":[{"award-number":["Other"]}],"id":[{"id":"10.13039\/100010269","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010269","name":"Wellcome Trust","doi-asserted-by":"publisher","award":["Other"],"award-info":[{"award-number":["Other"]}],"id":[{"id":"10.13039\/100010269","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010269","name":"Wellcome Trust","doi-asserted-by":"publisher","award":["Other"],"award-info":[{"award-number":["Other"]}],"id":[{"id":"10.13039\/100010269","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010269","name":"Wellcome Trust","doi-asserted-by":"publisher","award":["Other"],"award-info":[{"award-number":["Other"]}],"id":[{"id":"10.13039\/100010269","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010269","name":"Wellcome Trust","doi-asserted-by":"publisher","award":["Other"],"award-info":[{"award-number":["Other"]}],"id":[{"id":"10.13039\/100010269","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010269","name":"Wellcome Trust","doi-asserted-by":"publisher","award":["Other"],"award-info":[{"award-number":["Other"]}],"id":[{"id":"10.13039\/100010269","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Brief summary<\/jats:title>\n                    <jats:p>In early symptomatic COVID-19 treatment, high dose oral favipiravir did not accelerate viral clearance.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Favipiravir, an anti-influenza drug, has in vitro antiviral activity against SARS-CoV-2. Clinical trial evidence to date is inconclusive. Favipiravir has been recommended for the treatment of COVID-19 in some countries.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      In a multicentre open-label, randomised, controlled, adaptive platform trial, low-risk adult patients with early symptomatic COVID-19 were randomised to one of ten treatment arms including high dose oral favipiravir (3.6g on day 0 followed by 1.6g daily to complete 7 days treatment) or no study drug. The primary outcome was the rate of viral clearance (derived under a linear mixed-effects model from the daily log\n                      <jats:sub>10<\/jats:sub>\n                      viral densities in standardised duplicate oropharyngeal swab eluates taken daily over 8 days [18 swabs per patient]), assessed in a modified intention-to-treat population (mITT). The safety population included all patients who received at least one dose of the allocated intervention. This ongoing adaptive platform trial was registered at ClinicalTrials.gov (NCT05041907) on 13\/09\/2021.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>In the final analysis, the mITT population contained data from 114 patients randomised to favipiravir and 126 patients randomised concurrently to no study drug. Under the linear mixed-effects model fitted to all oropharyngeal viral density estimates in the first 8 days from randomisation (4,318 swabs), there was no difference in the rate of viral clearance between patients given favipiravir and patients receiving no study drug; a -1% (95% credible interval: -14 to 14%) difference. High dose favipiravir was well-tolerated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Interpretation<\/jats:title>\n                    <jats:p>Favipiravir does not accelerate viral clearance in early symptomatic COVID-19. The viral clearance rate estimated\u00a0from quantitative measurements of oropharyngeal eluate viral densities assesses the antiviral efficacy of drugs in vivo with comparatively few studied\u00a0patients.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12879-023-08835-3","type":"journal-article","created":{"date-parts":[[2024,1,15]],"date-time":"2024-01-15T06:02:18Z","timestamp":1705298538000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":30,"title":["Clinical antiviral efficacy of favipiravir in early COVID-19 (PLATCOV): an open-label, randomised, controlled, adaptive platform trial"],"prefix":"10.1186","volume":"24","author":[{"given":"Viravarn","family":"Luvira","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William H. K.","family":"Schilling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Podjanee","family":"Jittamala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James A.","family":"Watson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Boyd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanaya","family":"Siripoon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thundon","family":"Ngamprasertchai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedro J.","family":"Almeida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maneerat","family":"Ekkapongpisit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cintia","family":"Cruz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James J.","family":"Callery","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shivani","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Runch","family":"Tuntipaiboontana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Varaporn","family":"Kruabkontho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thatsanun","family":"Ngernseng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaruwan","family":"Tubprasert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad Yazid","family":"Abdad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Srisuda","family":"Keayarsa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wanassanan","family":"Madmanee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renato S.","family":"Aguiar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franciele M.","family":"Santos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pongtorn","family":"Hanboonkunupakarn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Borimas","family":"Hanboonkunupakarn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kittiyod","family":"Poovorawan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mallika","family":"Imwong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Walter R. J.","family":"Taylor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vasin","family":"Chotivanich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kesinee","family":"Chotivanich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sasithon","family":"Pukrittayakamee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arjen M.","family":"Dondorp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas P. J.","family":"Day","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mauro M.","family":"Teixeira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Watcharapong","family":"Piyaphanee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weerapong","family":"Phumratanaprapin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas J.","family":"White","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"the PLATCOV Collaborative Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,1,15]]},"reference":[{"key":"8835_CR1","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1128\/AAC.46.4.977-981.2002","volume":"46","author":"Y Furuta","year":"2002","unstructured":"Furuta Y, Takahashi K, Fukuda Y, Kuno M, Kamiyama T, Kozaki K, et al. In vitro and in vivo activities of anti-influenza virus compound T-705. Antimicrob Agents Chemother. 2002;46:977\u201381.","journal-title":"Antimicrob Agents Chemother"},{"key":"8835_CR2","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1016\/j.antiviral.2013.09.015","volume":"100","author":"Y Furuta","year":"2013","unstructured":"Furuta Y, Gowen BB, Takahashi K, Shiraki K, Smee DF, Barnard DL. Favipiravir (T-705), a novel viral RNA polymerase inhibitor. Antiviral Res. 2013;100:446\u201354.","journal-title":"Antiviral Res"},{"key":"8835_CR3","doi-asserted-by":"publisher","first-page":"e1001967","DOI":"10.1371\/journal.pmed.1001967","volume":"13","author":"D Sissoko","year":"2016","unstructured":"Sissoko D, Laouenan C, Folkesson E, M\u2019Lebing AB, Beavogui AH, Baize S, et al. Experimental treatment with favipiravir for ebola virus disease (the JIKI Trial): a historically controlled, single-arm proof-of-concept trial in Guinea. PLoS Med. 2016;13:e1001967.","journal-title":"PLoS Med"},{"key":"8835_CR4","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1038\/s41422-020-0282-0","volume":"30","author":"M Wang","year":"2020","unstructured":"Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020;30:269\u201371.","journal-title":"Cell Res"},{"key":"8835_CR5","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/j.cell.2020.05.034","volume":"182","author":"Q Wang","year":"2020","unstructured":"Wang Q, Wu J, Wang H, Gao Y, Liu Q, Mu A, et al. Structural basis for RNA replication by the SARS-CoV-2 polymerase. Cell. 2020;182:417\u201328.","journal-title":"Cell"},{"key":"8835_CR6","doi-asserted-by":"publisher","first-page":"2013","DOI":"10.1093\/jac\/dkaa171","volume":"75","author":"EA Coomes","year":"2020","unstructured":"Coomes EA, Haghbayan H. Favipiravir, an antiviral for COVID-19? J Antimicrob Chemother. 2020;75:2013\u20134.","journal-title":"J Antimicrob Chemother"},{"key":"8835_CR7","doi-asserted-by":"publisher","first-page":"2517","DOI":"10.1128\/AAC.01739-09","volume":"54","author":"K Sleeman","year":"2010","unstructured":"Sleeman K, Mishin VP, Deyde VM, Furuta Y, Klimov AI, Gubareva LV. In vitro antiviral activity of favipiravir (T-705) against drug-resistant influenza and 2009 A(H1N1) viruses. Antimicrob Agents Chemother. 2010;54:2517\u201324.","journal-title":"Antimicrob Agents Chemother"},{"key":"8835_CR8","doi-asserted-by":"publisher","first-page":"26955","DOI":"10.1073\/pnas.2014441117","volume":"117","author":"SJF Kaptein","year":"2020","unstructured":"Kaptein SJF, Jacobs S, Langendries L, Seldeslachts L, Ter Horst S, Liesenborghs L, et al. Favipiravir at high doses has potent antiviral activity in SARS-CoV-2-infected hamsters, whereas hydroxychloroquine lacks activity. Proc Natl Acad Sci USA. 2020;117:26955\u201365.","journal-title":"Proc Natl Acad Sci USA"},{"key":"8835_CR9","doi-asserted-by":"publisher","first-page":"1735","DOI":"10.1038\/s41467-021-21992-w","volume":"12","author":"JS Driouich","year":"2021","unstructured":"Driouich JS, Cochin M, Lingas G, Moureau G, Touret F, Petit PR, et al. Favipiravir antiviral efficacy against SARS-CoV-2 in a hamster model. Nat Commun. 2021;12:1735.","journal-title":"Nat Commun"},{"key":"8835_CR10","doi-asserted-by":"publisher","first-page":"4551","DOI":"10.2147\/IJGM.S349241","volume":"15","author":"PK Reddy","year":"2022","unstructured":"Reddy PK, Patil S, Khobragade A, Balki A, Raj A, Kalikar M, et al. Evaluation of the safety and efficacy of favipiravir in adult Indian patients with mild-to-moderate COVID-19 in a real-world setting. Int J Gen Med. 2022;15:4551\u201363.","journal-title":"Int J Gen Med"},{"key":"8835_CR11","doi-asserted-by":"publisher","first-page":"e31681","DOI":"10.1097\/MD.0000000000031681","volume":"101","author":"T Sitasuwan","year":"2022","unstructured":"Sitasuwan T, Phisalprapa P, Srivanichakorn W, Washirasaksiri C, Auesomwang C, Tinmanee R, et al. Early antiviral and supervisory dexamethasone treatment improve clinical outcomes of nonsevere COVID-19 patients. Medicine (Baltimore). 2022;101:e31681.","journal-title":"Medicine (Baltimore)"},{"issue":"10","key":"8835_CR12","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.1016\/j.eng.2020.03.007","volume":"6","author":"Q Cai","year":"2020","unstructured":"Cai Q, Yang M, Liu D, Chen J, Shu D, Xia J, et al. Experimental treatment with favipiravir for COVID-19: an open-label control study. Engineering. 2020;6(10):1192\u20138.","journal-title":"Engineering"},{"key":"8835_CR13","unstructured":"Doi Y, Ishihara T, Banno S, Ando M, Kondo M. Favipiravir Observational Study. Favipiravir for symptomatic COVID-19: a nationwide observational cohort study. J Infect Chemother. 2022:S1341\u2013321X(22)00291\u20134."},{"issue":"3","key":"8835_CR14","doi-asserted-by":"publisher","first-page":"397","DOI":"10.55519\/JAMC-03-10305","volume":"34","author":"B Abdulrahman","year":"2022","unstructured":"Abdulrahman B, Mady A, Odat MA, Tayar AA, Rana MA, Alharthy A, et al. Favipiravir efficacy and safety for the treatment of severe coronavirus disease 2019: a retrospective study. J Ayub Med Coll Abbottabad. 2022;34(3):397\u2013402.","journal-title":"J Ayub Med Coll Abbottabad"},{"key":"8835_CR15","doi-asserted-by":"publisher","first-page":"2197","DOI":"10.1080\/22221751.2022.2117092","volume":"11","author":"R Sirijatuphat","year":"2022","unstructured":"Sirijatuphat R, Manosuthi W, Niyomnaitham S, Owen A, Copeland KK, Charoenpong L, et al. Early treatment of Favipiravir in COVID-19 patients without pneumonia: a multicentre, open-labelled, randomized control study. Emerg Microbes Infect. 2022;11:2197\u2013206.","journal-title":"Emerg Microbes Infect"},{"key":"8835_CR16","doi-asserted-by":"publisher","first-page":"e01897","DOI":"10.1128\/AAC.01897-20","volume":"64","author":"Y Doi","year":"2020","unstructured":"Doi Y, Hibino M, Hase R, Yamamoto M, Kasamatsu Y, Hirose M, et al. Prospective, randomized, open-label trial of early versus late favipiravir therapy in hospitalized patients with COVID-19. Antimicrob Agents Chemother. 2020;64:e01897\u201320.","journal-title":"Antimicrob Agents Chemother."},{"key":"8835_CR17","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1016\/j.ijid.2020.11.008","volume":"102","author":"F Khamis","year":"2021","unstructured":"Khamis F, Al Naabi H, Al Lawati A, Ambusaidi Z, Al Sharji M, Al Barwani U, et al. Randomized controlled open label trial on the use of favipiravir combined with inhaled interferon beta-1b in hospitalized patients with moderate to severe COVID-19 pneumonia. Int J Infect Dis. 2021;102:538\u201343.","journal-title":"Int J Infect Dis"},{"key":"8835_CR18","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1093\/cid\/ciaa1176","volume":"73","author":"AA Ivashchenko","year":"2021","unstructured":"Ivashchenko AA, Dmitriev KA, Vostokova NV, Azarova VN, Blinow AA, Egorova AN, et al. AVIFAVIR for treatment of patients with moderate coronavirus disease 2019 (COVID-19): interim results of a phase ii\/iii multicenter randomized clinical trial. Clin Infect Dis. 2021;73:531\u20134.","journal-title":"Clin Infect Dis"},{"key":"8835_CR19","doi-asserted-by":"crossref","unstructured":"Zhao H, Zhang C, Zhu Q, Chen X, Chen G, Sun W, et al. Favipiravir in the treatment of patients with SARS-CoV-2 RNA recurrent positive after discharge: a multicenter, open-label, randomized trial. Int Immunopharmacol. 2021;97:107702.","DOI":"10.1016\/j.intimp.2021.107702"},{"key":"8835_CR20","doi-asserted-by":"publisher","first-page":"107522","DOI":"10.1016\/j.intimp.2021.107522","volume":"95","author":"M Solaymani-Dodaran","year":"2021","unstructured":"Solaymani-Dodaran M, Ghanei M, Bagheri M, Qazvini A, Vahedi E, Hassan Saadat S, et al. Safety and efficacy of Favipiravir in moderate to severe SARS-CoV-2 pneumonia. Int Immunopharmacol. 2021;95:107522.","journal-title":"Int Immunopharmacol"},{"key":"8835_CR21","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.ijid.2020.11.142","volume":"103","author":"ZF Udwadia","year":"2021","unstructured":"Udwadia ZF, Singh P, Barkate H, Patil S, Rangwala S, Pendse A, et al. Efficacy and safety of favipiravir, an oral RNA-dependent RNA polymerase inhibitor, in mild-to-moderate COVID-19: a randomized, comparative, open-label, multicenter, phase 3 clinical trial. Int J Infect Dis. 2021;103:62\u201371.","journal-title":"Int J Infect Dis"},{"issue":"1","key":"8835_CR22","doi-asserted-by":"publisher","first-page":"4925","DOI":"10.1038\/s41598-022-08794-w","volume":"12","author":"M Al Qahtani","year":"2022","unstructured":"Al Qahtani M, Kumar N, Aljawder D, Abdulrahman A, Mohamed MW, Alnashaba F, et al. Randomized controlled trial of favipiravir, hydroxychloroquine, and standard care in patients with mild\/moderate COVID-19 disease. Sci Rep. 2022;12(1):4925.","journal-title":"Sci Rep"},{"key":"8835_CR23","doi-asserted-by":"publisher","first-page":"3184","DOI":"10.1002\/jmv.27724","volume":"94","author":"M Hassaniazad","year":"2022","unstructured":"Hassaniazad M, Farshidi H, Gharibzadeh A, Bazram A, Khalili E, Noormandi A, Fathalipour M. Efficacy and safety of favipiravir plus interferon-beta versus lopinavir\/ritonavir plus interferon-beta in moderately ill patients with COVID-19: a randomized clinical trial. J Med Virol. 2022;94:3184\u201391.","journal-title":"J Med Virol"},{"key":"8835_CR24","doi-asserted-by":"publisher","first-page":"101703","DOI":"10.1016\/j.eclinm.2022.101703","volume":"54","author":"JH McMahon","year":"2022","unstructured":"McMahon JH, Lau JSY, Coldham A, Roney J, Hagenauer M, Price S, et al. Favipiravir in early symptomatic COVID-19, a randomised placebo-controlled trial. EClinicalMedicine. 2022;54:101703.","journal-title":"EClinicalMedicine"},{"key":"8835_CR25","doi-asserted-by":"publisher","first-page":"e1004120","DOI":"10.1371\/journal.pmed.1004120","volume":"19","author":"DM Lowe","year":"2022","unstructured":"Lowe DM, Brown LK, Chowdhury K, Davey S, Yee P, Ikeji F, et al. Favipiravir, lopinavir-ritonavir, or combination therapy (FLARE): a randomised, double-blind, 2 \u00d7 2 factorial placebo-controlled trial of early antiviral therapy in COVID-19. PLoS Med. 2022;19:e1004120.","journal-title":"PLoS Med"},{"key":"8835_CR26","first-page":"ciac712","volume":"6","author":"Y Golan","year":"2022","unstructured":"Golan Y, Campos JAS, Woolson R, Cilla D, Hanabergh R, Gonzales-Rojas Y, et al. Favipiravir in patients with early mild-to-moderate COVID-19: a randomized controlled trial. Clin Infect Dis. 2022;6:ciac712.","journal-title":"Clin Infect Dis."},{"key":"8835_CR27","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1016\/j.cmi.2021.12.026","volume":"28","author":"M Bosaeed","year":"2022","unstructured":"Bosaeed M, Alharbi A, Mahmoud E, Alrehily S, Bahlaq M, Gaifer Z, et al. Efficacy of favipiravir in adults with mild COVID-19: a randomized, double-blind, multicentre, placebo-controlled clinical trial. Clin Microbiol Infect. 2022;28:602\u20138.","journal-title":"Clin Microbiol Infect"},{"key":"8835_CR28","doi-asserted-by":"publisher","first-page":"e432","DOI":"10.1093\/cid\/ciab962","volume":"75","author":"CH Chuah","year":"2022","unstructured":"Chuah CH, Chow TS, Hor CP, Cheng JT, Ker HB, Lee HG, et al. Efficacy of early treatment with favipiravir on disease progression among high-risk patients with coronavirus disease 2019 (COVID-19): a randomized open-label clinical trial. Clin Infect Dis. 2022;75:e432\u20139.","journal-title":"Clin Infect Dis"},{"key":"8835_CR29","doi-asserted-by":"publisher","first-page":"1883","DOI":"10.1093\/cid\/ciac312","volume":"75","author":"M Holubar","year":"2022","unstructured":"Holubar M, Subramanian A, Purington N, Hedlin H, Bunning B, Walter KS, et al. Favipiravir for treatment of outpatients with asymptomatic or uncomplicated coronavirus disease 2019: a double-blind, randomized, placebo-controlled, phase 2 trial. Clin Infect Dis. 2022;75:1883\u201392.","journal-title":"Clin Infect Dis"},{"key":"8835_CR30","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1002\/em.22471","volume":"63","author":"MD Waters","year":"2022","unstructured":"Waters MD, Warren S, Hughes C, Lewis P, Zhang F. Human genetic risk of treatment with antiviral nucleoside analog drugs that induce lethal mutagenesis: the special case of molnupiravir. Environ Mol Mutagen. 2022;63:37\u201363.","journal-title":"Environ Mol Mutagen"},{"key":"8835_CR31","doi-asserted-by":"publisher","unstructured":"Schilling WHK, Jittamala P, Watson JA, Boyd S, Luvira V, Siripoon T, et al. Antiviral efficacy of molnupiravir versus ritonavir-boosted nirmatrelvir in patients with early symptomatic COVID-19 (PLATCOV): an open-label, phase 2, randomised, controlled, adaptive trial. Lancet Infect Dis. 2023:S1473-3099(23)00493-0. https:\/\/doi.org\/10.1016\/S1473-3099(23)00493-0. Epub ahead of print. Erratum in: Lancet Infect Dis. 2023;23(12):e511.","DOI":"10.1016\/S1473-3099(23)00493-0"},{"key":"8835_CR32","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1002\/cpt.1844","volume":"108","author":"YX Du","year":"2020","unstructured":"Du YX, Chen XP. Favipiravir: pharmacokinetics and concerns about clinical trials for 2019-nCoV infection. Clin Pharmacol Ther. 2020;108:242\u20137.","journal-title":"Clin Pharmacol Ther"},{"key":"8835_CR33","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1056\/NEJMoa2116044","volume":"386","author":"A Jayk Bernal","year":"2022","unstructured":"Jayk Bernal A, Gomes da Silva MM, Musungaie DB, Kovalchuk E, Gonzalez A, Delos Reyes V, et al. Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients. N Engl J Med. 2022;386:509\u201320.","journal-title":"N Engl J Med"},{"key":"8835_CR34","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1056\/NEJMoa2118542","volume":"386","author":"J Hammond","year":"2022","unstructured":"Hammond J, Leister-Tebbe H, Gardner A, Abreu P, Bao W, Wisemandle W, et al. Oral nirmatrelvir for high-risk, nonhospitalized adults with Covid-19. N Engl J Med. 2022;386:1397\u2013408.","journal-title":"N Engl J Med"},{"key":"8835_CR35","doi-asserted-by":"publisher","first-page":"e0005389","DOI":"10.1371\/journal.pntd.0005389","volume":"11","author":"TH Nguyen","year":"2017","unstructured":"Nguyen TH, Guedj J, Anglaret X, Laou\u00e9nan C, Madelain V, Taburet AM, et al. Favipiravir pharmacokinetics in Ebola-Infected patients of the JIKI trial reveals concentrations lower than targeted. PLoS Negl Trop Dis. 2017;11:e0005389.","journal-title":"PLoS Negl Trop Dis"},{"key":"8835_CR36","doi-asserted-by":"publisher","unstructured":"Schilling WHK, Jittamala P, Watson JA, Ekkapongpisit M, Siripoon T, Ngamprasertchai T, et al. Pharmacometrics of high-dose ivermectin in early COVID-19 from an open label, randomized, controlled adaptive platform trial (PLATCOV). Elife. 2023;12:e83201. https:\/\/doi.org\/10.7554\/eLife.83201.","DOI":"10.7554\/eLife.83201"},{"key":"8835_CR37","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1056\/NEJMoa2115869","volume":"386","author":"G Reis","year":"2022","unstructured":"Reis G, Silva EASM, Silva DCM, Thabane L, Milagres AC, Ferreira TS, et al. Effect of early treatment with ivermectin among patients with Covid-19. N Engl J Med. 2022;386:1721\u201331.","journal-title":"N Engl J Med"},{"issue":"10","key":"8835_CR38","doi-asserted-by":"publisher","first-page":"1318","DOI":"10.1093\/infdis\/jiad275","volume":"228","author":"P Jittamala","year":"2023","unstructured":"Jittamala P, Schilling WHK, Watson JA, Luvira V, Siripoon T, Ngamprasertchai T, et al. Clinical antiviral efficacy of remdesivir in COVID-19: an open label, randomized, controlled adaptive platform trial (PLATCOV). J Infect Dis. 2023;228(10):1318\u201325. https:\/\/doi.org\/10.1093\/infdis\/jiad275.","journal-title":"J Infect Dis"},{"key":"8835_CR39","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1056\/NEJMoa2116846","volume":"386","author":"RL Gottlieb","year":"2022","unstructured":"Gottlieb RL, Vaca CE, Paredes R, Mera J, Webb BJ, Perez G, et al. Early remdesivir to prevent progression to severe Covid-19 in outpatients. N Engl J Med. 2022;386:305\u201315.","journal-title":"N Engl J Med"},{"key":"8835_CR40","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1056\/NEJMoa2035002","volume":"384","author":"DM Weinreich","year":"2021","unstructured":"Weinreich DM, Sivapalasingam S, Norton T, Ali S, Gao H, Bhore R, et al. REGN-COV2, a neutralizing antibody cocktail, in outpatients with COVID-19. N Engl J Med. 2021;384:238\u201351.","journal-title":"N Engl J Med"},{"key":"8835_CR41","doi-asserted-by":"publisher","first-page":"1184","DOI":"10.1056\/NEJMoa2109682","volume":"385","author":"MP O'Brien","year":"2021","unstructured":"O\u2019Brien MP, Forleo-Neto E, Musser BJ, Isa F, Chan KC, Sarkar N, et al. Covid-19 phase 3 prevention trial team. Subcutaneous REGEN-COV antibody combination to prevent Covid-19. N Engl J Med. 2021;385:1184\u201395.","journal-title":"N Engl J Med."},{"key":"8835_CR42","doi-asserted-by":"publisher","first-page":"eabl7430","DOI":"10.1126\/scitranslmed.abl7430","volume":"14","author":"WA Fischer 2nd","year":"2022","unstructured":"Fischer WA 2nd, Eron JJ Jr, Holman W, Cohen MS, Fang L, Szewczyk LJ, et al. A phase 2a clinical trial of molnupiravir in patients with COVID-19 shows accelerated SARS-CoV-2 RNA clearance and elimination of infectious virus. Sci Transl Med. 2022;14:eabl7430.","journal-title":"Sci Transl Med"},{"key":"8835_CR43","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/S0140-6736(22)02597-1","volume":"401","author":"CC Butler","year":"2023","unstructured":"Butler CC, Hobbs DR, Gbinigie OA, Rahman NM, Hayward G, Richards DB, et al. Molnupiravir plus usual care versus usual care alone as early treatment for adults with COVID-19 at increased risk of adverse outcomes (PANORAMIC): an open-label, platform-adaptive randomised controlled trial. Lancet. 2023;401:281\u201393.","journal-title":"Lancet"},{"key":"8835_CR44","doi-asserted-by":"publisher","first-page":"e0019222","DOI":"10.1128\/aac.00192-22","volume":"66","author":"JA Watson","year":"2022","unstructured":"Watson JA, Kissler SM, Day NPJ, Grad YH, White NJ. Characterizing SARS-CoV-2 viral clearance kinetics to improve the design of antiviral pharmacometric studies. Antimicrob Agents Chemother. 2022;66:e0019222.","journal-title":"Antimicrob Agents Chemother"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-023-08835-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-023-08835-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-023-08835-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,15]],"date-time":"2024-01-15T18:01:47Z","timestamp":1705341707000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-023-08835-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,15]]},"references-count":44,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["8835"],"URL":"https:\/\/doi.org\/10.1186\/s12879-023-08835-3","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-2675703\/v1","asserted-by":"object"}]},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,15]]},"assertion":[{"value":"10 March 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 November 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 January 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All patients provided fully informed written consent. The trial was approved by local and national research ethics boards in Thailand (Faculty of Tropical Medicine Ethics Committee, Mahidol University, FTMEC Ref: TMEC 21\u2013058) and the Central Research Ethics Committee (CREC, Bangkok, Thailand, CREC Ref: CREC048\/64BP-MED34), in Brazil by the Research Ethics Committee of the Universidade Federal de Minas Gerais (COEP-UFMG, Minas Gerais, Brazil, COEP-UFMG) and National Research Ethics Commission- (CONEP, Brazil, COEP-UFMG and CONEP Ref: CAAE:51593421.1.0000.5149), and by the Oxford University Tropical Research Ethics Committee (OxTREC, Oxford, UK, OxTREC Ref: 24\u201321). All methods were performed in accordance with the relevant guidelines and regulations (e.g. Declaration of Helsinki).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"89"}}